AI
FULC icon

Allostery Investments’s Fulcrum Therapeutics FULC Stock Holding History

Allostery Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,353
Closed -$278K – 11
2025
Q2 		$278K Buy
+40,353
New +$216K 3.54% 9

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allostery Investments's FULC Position: Q3 2025 in Review

Allostery Investments sold out of Fulcrum Therapeutics (FULC) in Q3 2025, closing a stake of 40,353 shares — an estimated $278K sold.

Allostery Investments first reported a position in FULC in Q2 2025 and held it in 1 quarter. The position peaked at $278K in Q2 2025. 129 funds tracked by Wall St. Rank hold FULC as of Q3 2025.

  • Allostery Investments reported no remaining Fulcrum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Allostery Investments sold 40,353 Fulcrum Therapeutics shares in Q3 2025, an estimated $278K.
  • Allostery Investments first reported a position in Fulcrum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Allostery Investments's Fulcrum Therapeutics position peaked at $278K in Q2 2025.
  • 129 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.